SEC Filing Summary: Revelation Biosciences, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Revelation Biosciences, Inc. on November 10, 2022. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2022, and to provide program updates. The company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It references a press release (Exhibit 99.1) that contains the comparative financial results and program updates.
Guidance, Outlook, and Risks
Management commentary and program updates were issued via a press release on November 10, 2022. The filing explicitly states that the information in Item 2.02, Item 7.01, and Exhibit 99.1 will not be treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated. No specific risks or contingencies are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2022) for specific revenue, net loss, and cash position figures.
- Verify the details of the program updates mentioned in Item 7.01.
- Confirm the status of the company's securities (Units REVBU, Common Stock REVB, Warrants REVBW) on the NASDAQ Stock Market.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in this report.